Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial

Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment

Empowering Undergraduates: Johns Hopkins BME Design Team Transforms Healthcare Solutions

Biomedical Engineering, Undergraduate Design Team, Healthcare Innovation, Clinical Challenges, Design Principles, Team-Based Projects, Entrepreneurship, Intellectual Property, Regulatory Frameworks